VolitionRx Cash And Cash Equivalents As Of December 31, 2023, Totaled ~$20.7M
Portfolio Pulse from Benzinga Newsdesk
VolitionRx Limited (VNRX) reported a significant increase in cash and cash equivalents, totaling approximately $20.7 million as of December 31, 2023, compared to $10.9 million the previous year. The company also saw a 153% increase in revenue, reaching about $775,000 in 2023, and received $13.0 million in milestone payments from Heska Corporation in December 2023. However, net cash used in operating activities was $18.1 million for the year. VolitionRx will host a conference call on March 26, 2024, to discuss these financial highlights and other updates.
March 25, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
VolitionRx Limited reported a significant increase in cash and cash equivalents, a 153% increase in revenue, and received $13.0 million from Heska Corporation, indicating strong financial performance and strategic partnerships.
The substantial increase in cash and cash equivalents, along with a significant revenue growth and the receipt of milestone payments from a partnership, are positive indicators of VolitionRx's financial health and operational success. These factors are likely to be viewed positively by investors, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100